 CRANBURY, N.J., April 27, 2022 GLOBE NEWSWIRE -- PMV Pharmaceuticals, Inc. Nasdaq: PMVP, a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that initial clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 12 study evaluating PC14586 have been selected for oral presentation at the 2022 American Society of Clinical Oncology ASCO Annual Meeting, to take place June 3-7, in Chicago, Illinois. 